(BLRX) BioLineRx - Ratings and Ratios

BioLineRx Ltd (NASDAQ:BLRX) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative therapeutics for oncology and rare diseases. The companys lead candidate, APHEXDA (motixafortide), is a synthetic peptide currently in Phase 1 clinical trials for sickle cell disease and Phase 2b trials for pancreatic cancer. APHEXDA has also completed a Phase 3 trial for multiple myeloma, demonstrating its potential as a versatile therapeutic agent. Additionally, BioLineRx is advancing BL-5010, a pen-like applicator designed for the non-surgical removal of skin lesions, leveraging its proprietary acidic aqueous solution technology. The company, incorporated in 2003 and headquartered in Hevel Modiin, Israel, collaborates with academic research institutions and industry partners to expand its pipeline, which includes early-stage assets targeting unmet medical needs.

From a technical standpoint, BLRX is currently trading below its 20-day and 50-day moving averages, with the stock price at 3.18, below the SMA 20 (3.47) and SMA 50 (4.86). The ATR of 0.27 indicates moderate volatility. Fundamentally, the company has a market cap of $11.80M, with a P/S ratio of 0.54, reflecting its early-stage commercialization. The negative P/E and RoE of -79.13 highlight ongoing operational losses, while the P/B ratio of 1.34 suggests that the market values the companys assets above book value.